 Artist: Rush: mp3 download Genre(s): Rock: Hard-Rock Rock Rock: Progressive Rock: Electronic Rush's discography:  Snakes and Arrows Year: 2007 Tracks: 13  Feedback Year: 2004 Tracks: 8  Rush In Rio (CD 3) Year: 2003 Tracks: 8  Rush In Rio (CD 2) Year: 2003 Tracks: 10  Rush In Rio (CD 1) Year: 2003 Tracks: 13  Vapor Trails Year: 2002 Tracks: 13  Different Stages - Live (CD 3) Year: 1998 Tracks: 11  Different Stages - Live (CD 1) Year: 1998 Tracks: 16  Different Stages (Disc 2) Year: 1998 Tracks: 12  Retrospective Vol. 2 Year: 1997 Tracks: 15  Test for Echo Year: 1996 Tracks: 11  Counterparts Year: 1993 Tracks: 11  Roll The Bones Year: 1991 Tracks: 10  Presto Year: 1989 Tracks: 11  A Show of Hands Year: 1989 Tracks: 15  Hold Your Fire Year: 1987 Tracks: 10  A Farewell To Kings Year: 1986 Tracks: 6  Power Windows Year: 1985 Tracks: 8  Grace Under Pressure Year: 1984 Tracks: 8  Signals Year: 1982 Tracks: 8  Moving Pictures Year: 1981 Tracks: 7  Permanent Waves Year: 1980 Tracks: 6  All The World's A Stage Year: 1976 Tracks: 10  Fly By Night Year: 1975 Tracks: 8  Caress of Steel Year: 1975 Tracks: 5  Retrospective I (1974-1980) Year: Tracks: 14 Over the line of their decades-spanning career, the Canadian ability ternion Rush emerged as one of hard rock's nigh extremely regarded bands; although typically brushed aside by critics and although rarefied recipients of mainstream drink down radiocommunication airplay, the mathematical group nevertheless south Korean north Korean won an impressive and devoted fan following patch their hotshot implementation skills solidified their standing as musicians' musicians. Rushing formed in Toronto, Ontario, in the autumn of 1968, and initially comprised guitar player Alex Lifeson (born Alexander Zivojinovich), vocalist/bassist Geddy Lee (born Gary Lee Weinrib), and drummer John Rutsey. In their primary personification, the triad john Drew a heavy influence from Cream, and honed their skills on the Toronto club circuit before issuance their debut single, a rendition of Buddy Holly's "Non Fade Away," in 1973. A self-titled LP followed in 1974, at which time Rutsey exited; he was replaced by drummer Neil Peart, wHO as well put on the role of the band's primary ballad maker, composition the cerebral lyrics (influenced by plant of science fiction and illusion) that bit by bit became a earmark of the group's aesthetic. With Peart firmly ensconced, Rush returned in 1975 with a geminate of LPs, Fly by Night and Caress of Steel. Their side by side campaign, 1976's 2112, proven to be their breakthrough release: a futurist construct album based on the ketubim of Ayn Rand, it coalesced the elements of the trio's sound -- Lee's high vocals, Peart's epic-length compositions, and Lifeson's composite guitar act upon -- into a co-ordinated whole. Fans loved it -- 2112 was the low geartrain in a long tonal pattern of gold and atomic number 78 releases -- spell critics laid-off it as grandiloquent and pretentious: either way, it established a formula from which the set rarely deviated throughout the continuance of their occupational group. A Farewell to Kings followed in 1977 and reached the Top 40 in both the U.S. and Britain. After 1978's Hemispheres, Rush achieved tied greater popularity with 1980's Permanent Waves, a criminal record pronounced by Peart's dramatic dislodge into shorter, less sprawling compositions; the single "The Spirit of Radio" tied became a major hit. With 1981's Moving Pictures, the triad scored some other hit of sorts with "Tomcat Sawyer," which garnered clayey exposure on album-oriented wireless and became perchance their best-known song. As the eighties continued, Rush grew into a phenomenally popular live draw as albums like 1982's Signals (which generated the bankrupt "Newfangled World Man"), 1984's Grace Under Pressure, and 1985's Exponent Windows continued to sell millions of copies. As the decennium john Drew to a close, the trio cut plump for on its touring docket spell hardcore following complained of a sameness afflicting oilskin, synth-driven efforts like 1987's Keep Your Fire and 1989's Presto. At the dawn of the 1990s, withal, Rush returned to the heavier legal of their early records and set a renewed emphasis on Lifeson's guitar heroics; consequently, both 1991's Turn over the Bones and 1993's Counterparts reached the Top Three on the U.S. album charts. In 1996, the band issued Test for Echo and headed out on the road the following summertime. Shortly thereafter, Peart lost his girl in an auto chance event. Tragedy smitten once again in 1998 when Peart's wife succumbed to crab. Dire multiplication in the Rush camp did non causal agency the lot to lay off. Lee took prison term out for a solo stint with 2000's My Favorite Headache; however, rumors of the band playing in the studio began to pass around. It would be five-spot old age until anything surfaced from the band. Fans were reassured in early 2002 by news that Rush were recording new songs in Toronto. The fruit of those roger Sessions light-emitting diode to the button of Rush's seventeenth studio album, Vapour Trails, later that spring. In 2004 the band embarked on their 30th anniversary turn, and in 2006 they returned to the studio to begin work on a new record album. The resulting Snakes & Arrows was released in May 2007. |
Saturday 30 August 2008
Mp3 music: Rush
Wednesday 20 August 2008
The precocious ones: Meet Massachusetts' musical prodigies
Pete Townshend would be proud. The kids in Massachusetts ar way more than alright.
Massachusetts� new new kids on the occlude don�t wear acid-washed jeans and lump on the hair colloidal gel; their claim to renown doesn�t involve synchronized dance or Tiger Beat-ready smiles. Instead, today�s young Bay State endowment has a decidedly adult take on music.
From a 9-year-old rockin� some strikingly authentic galvanizing Chicago blues with Buddy Guy to a 16-year-old playing building complex post-bop duets with Lee Konitz to a group of high school kids re-perfecting Elvis Costello-influenced power pop, the state�s hottest young artists have artistic ambitions that outshine the Hannah Montana pop of their peers.
Quinn Sullivan
Sitting in his parents� basement in New Bedford surrounded by a 6 guitars, 9-year-old Quinn picks out the Beatles� �Blackbird.� His petite fingers creep up and down the fret board forming tortuous chords. Then his young voice joins in, mixture Massachusetts with Paul McCartney�s Liverpudlian accent.
�Blackbird singing in the numb of night!� belts Quinn.
It�s cute, even impressive. But it�s just the tip of Quinn�s brilliance.
After finishing with the Fab Four, he straps on his Stratocaster and plugs in. Blues licks bounce around the basement, reechoing like Clapton�s guitar at its rawest, most chaotic and wild.
�The Beatles and Clapton and Buddy Guy, that�s by and large what I like to listen to,� says the soft-spoken and humble Quinn as he wails away.
�My friends like the stuff on Kiss-108,� he says, making a face like a plate of overcooked lima beans was dropped in front on him.
Guy took the primary school guitar whiz under his wing last yr. Sullivan guests on Guy�s new album, �Skin Deep,� and volition join the blues legend for a tune or two at his Bank of America Pavilion gig on Sunday.
�When I was Quinn�s long time I didn�t know what a guitar was,� Guy aforesaid from a Virginia duty tour stop. �When I observed the guitar I couldn�t afford nonpareil, so I used to put 2 nails in the wall with deuce rubber bands, trying to come up with a guitar sound. So it�s great Quinn�s started so young.
�The first time I brought him onstage I was knocked out by his playacting,� Guy continued. �He kept looking for up at me like he was saying, �Show me something I don�t already know.� �
The two met a year ago backstage before Guy�s show at the Zeiterion Theatre in New Bedford.
�Quinn gave Buddy his guitar to sign and Buddy asked, �You wanna play a couple riffs on that?� � Quinn�s dad Terry Sullivan recalled. �So he played something and Buddy was just blown away. He said, �You better be ready tonight when I call in you up.� �
More info
Sunday 10 August 2008
Novel Assay Finds That Widely Prescribed Anti-Parasite Drug Targets Cancer-Causing Protein
�Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug secondhand globally to treat parasitical infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
Because most patients with metastatic melanoma fail to react to useable therapies, the discovery of a viable investigational discourse with an established safe profile could address a serious unmet need in oncology. Effectively sidestepping the prohibitive costs and long lead multiplication typically required to discover new genus Cancer medicines, the NYU squad screened a library of already approved drugs for activity against the near deadly shape of skin cancer.
Their report, which was selected for throw out online publication by Molecular Cancer Research, is promulgated in the August consequence of the journal. Since submitting the article for publication, the authors have conducted extra pre-clinical studies of mebendazole in an in vivo model of chemotherapy-resistant malignant melanoma and ar now preparing a phase angle I clinical trial, expected to start next year at NYU Cancer Institute.
"While rational drug plan remains a perfectly valid way to develop crab therapies, we also penury approaches that are less costly and more productive of new effective treatments," said lead author Seth J. Orlow, M.D. Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "You could say this is more than of a guerrilla approach. Instead of screening millions of untested compounds for an factor that inhibits or stimulates a special molecular target, we chose to screen a turgid library of already approved drugs for novel activity against malignant melanoma cells, and then upgrade the to the highest degree promising candidate rapidly to clinical practice."
First, the NYU researchers screened a library of 2,000 well-known drugs [Spectrum Collection (Microsource Discovery Systems)] and identified members of the benzimidazole kinsperson for their ability to inhibit melanoma growth and induce programmed cell death (apoptosis) of malignant malignant melanoma cells without affecting normal melanocytes (pigment-producing cells). Of the identified benzimidazoles, the team selected mebendazole for further work because it was known to be a well-tolerated, orally available drug with anti-cancer properties.
In a surprising find, the team found that mebendazole takes advantage of a exceptional difference 'tween a malignant melanoma cell and normal melanocytes. Melanomas produce high levels of a protein called Bcl-2, which is known to protect certain cancer cells from apoptosis. The team sawing machine that when a malignant melanoma cancer cell was exposed to mebendazole, it resulted in inactivation of Bcl-2, allowing programmed cell death to occur.
Mebendazole, sold as a generic drug in the United States, has been used since the 1970s to process roundworm, hookworm, pinworm, whipworm, and other worm-based parasitical infections. Previous research has shown it to have some anticancer activity in lung and adrenocortical crab.
"Our ability to identify novel treatments for melanoma and advance them chop-chop into the clinic identical much depends on NYU's multidisciplinary approaching to melanoma care and research," Dr. Orlow aforesaid. "To be effective, translational medicine cannot be unidirectional. Discovery moves continuously back and forward between the clinic and the bench. We are now focused on determining the chain of mountains of doses to be tested in the clinic, whether specific types of melanomas will respond better than others, and whether combining mebendazole with other agents testament be of further benefit"
The authors of this study are NYU Cancer Institute researchers Nicole Doudican, Adrianna Rodriguez, Iman Osman, and Seth J. Orlow. The study was supported by private beneficent grants.
NYU Langone Medical Center / New York University School of Medicine
More info
Because most patients with metastatic melanoma fail to react to useable therapies, the discovery of a viable investigational discourse with an established safe profile could address a serious unmet need in oncology. Effectively sidestepping the prohibitive costs and long lead multiplication typically required to discover new genus Cancer medicines, the NYU squad screened a library of already approved drugs for activity against the near deadly shape of skin cancer.
Their report, which was selected for throw out online publication by Molecular Cancer Research, is promulgated in the August consequence of the journal. Since submitting the article for publication, the authors have conducted extra pre-clinical studies of mebendazole in an in vivo model of chemotherapy-resistant malignant melanoma and ar now preparing a phase angle I clinical trial, expected to start next year at NYU Cancer Institute.
"While rational drug plan remains a perfectly valid way to develop crab therapies, we also penury approaches that are less costly and more productive of new effective treatments," said lead author Seth J. Orlow, M.D. Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "You could say this is more than of a guerrilla approach. Instead of screening millions of untested compounds for an factor that inhibits or stimulates a special molecular target, we chose to screen a turgid library of already approved drugs for novel activity against malignant melanoma cells, and then upgrade the to the highest degree promising candidate rapidly to clinical practice."
First, the NYU researchers screened a library of 2,000 well-known drugs [Spectrum Collection (Microsource Discovery Systems)] and identified members of the benzimidazole kinsperson for their ability to inhibit melanoma growth and induce programmed cell death (apoptosis) of malignant malignant melanoma cells without affecting normal melanocytes (pigment-producing cells). Of the identified benzimidazoles, the team selected mebendazole for further work because it was known to be a well-tolerated, orally available drug with anti-cancer properties.
In a surprising find, the team found that mebendazole takes advantage of a exceptional difference 'tween a malignant melanoma cell and normal melanocytes. Melanomas produce high levels of a protein called Bcl-2, which is known to protect certain cancer cells from apoptosis. The team sawing machine that when a malignant melanoma cancer cell was exposed to mebendazole, it resulted in inactivation of Bcl-2, allowing programmed cell death to occur.
Mebendazole, sold as a generic drug in the United States, has been used since the 1970s to process roundworm, hookworm, pinworm, whipworm, and other worm-based parasitical infections. Previous research has shown it to have some anticancer activity in lung and adrenocortical crab.
"Our ability to identify novel treatments for melanoma and advance them chop-chop into the clinic identical much depends on NYU's multidisciplinary approaching to melanoma care and research," Dr. Orlow aforesaid. "To be effective, translational medicine cannot be unidirectional. Discovery moves continuously back and forward between the clinic and the bench. We are now focused on determining the chain of mountains of doses to be tested in the clinic, whether specific types of melanomas will respond better than others, and whether combining mebendazole with other agents testament be of further benefit"
The authors of this study are NYU Cancer Institute researchers Nicole Doudican, Adrianna Rodriguez, Iman Osman, and Seth J. Orlow. The study was supported by private beneficent grants.
NYU Langone Medical Center / New York University School of Medicine
More info
Subscribe to:
Posts (Atom)